Cholestech begins US delivery of liver enzyme test:
This article was originally published in Clinica
Executive Summary
Hayward, California-based diagnostics developer Cholestech has begun shipping in the US its Aspartate Aminotransferase (AST) test for assessing damage to the liver due to drugs or certain diseases. The assay, the only CLIA-waivered one of its kind, runs on Cholestech's LDX system in conjunction with its other liver enzyme test, Alanine Aminotransferase (ALT). Nearly 200 million ALT and AST tests are ordered in the US each year, says Cholestech.